[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340714-105":59,"doc-detail-340714-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parp-inhibition-radiosensitizes-brca1-wildtype-and-mutated-breast-cancer-to-proton-therapy","PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy","","Aggressive breast cancers often fail or acquire resistance to radiotherapy, motivating strategies that enhance tumor response. This study examined whether PARP inhibition radiosensitizes BRCA1-mutated and BRCA1 wildtype breast cancer models to proton therapy versus photon radiotherapy. Two BRCA1-mutated cell line pairs and their isogenic BRCA1-recovered counterparts were treated with PARP inhibitors and irradiated. Protons produced higher cell kill, and PARP inhibition amplified killing and DNA damage regardless of BRCA1 status, with stronger tumor growth delay in vivo.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parp-inhibition-radiosensitizes-brca1-wildtype-and-mutated-breast-cancer-to-proton-therapy/340714/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parp-inhibition-radiosensitizes-brca1-wildtype-and-mutated-breast-cancer-to-proton-therapy/340714.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the study?","Question",{"text":112,"@type":113},"To determine whether PARP inhibition can radiosensitize breast cancer models to proton therapy and improve response relative to standard photon radiotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Does the radiosensitization depend on BRCA1 mutation status?",{"text":117,"@type":113},"No. PARP inhibition increased the radiosensitization effects for both photons and protons independent of BRCA1 status.",{"name":119,"@type":110,"acceptedAnswer":120},"What combination produced the strongest anti-tumor effect in vivo?",{"text":121,"@type":113},"The combination of proton irradiation (3.99 keV/µm) with PARP inhibition resulted in the greatest tumor growth delay and the highest survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340714,1790159898,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy  \nMariam Ben Kacem1,4􀀍, Scott J. Bright1􀀍, Emma Moran1, David B. Flint1, David K. J. Martinus1, Broderick X. Turner1,4, Ilsa Qureshi1,5, Rishab Kolachina1,2, Mandira Manandhar1, Poliana C. Marinello1􀀍, Simona F. Shaitelman3􀀍 &  \nGabriel O. Sawakuchi1􀀍  \nAggressive breast cancers often fail or acquire resistance to radiotherapy. To develop new strategies to improve the outcome of aggressive breast cancer patients, we studied how PARP inhibition radiosensitizes breast cancer models to proton therapy, which is a radiotherapy modality that generates more DNA damage in the tumor than standard radiotherapy using photons. Two human BRCA1-mutated breast cancer cell lines and their isogenic BRCA1-recovered pairs were treated with a PARP inhibitor and irradiated with photons or protons. Protons (9.9 and 3.85 keV/µm) induced higher cell kill independent of BRCA1 status. PARP inhibition amplified the cell kill effect to both photons and protons (9.9 and 3.85 keV/µm) independent of BRCA1 status. Numbers of γH2AX foci, micronuclei, and cGAS-positive micronuclei were significantly higher in BRCA1-mutated cells. Cell cycle distribution and stress-induced senescence were not affected by PARP inhibition in our cell lines. In vivo, the combination of protons (3.99 keV/µm) and PARP inhibition induced the greatest tumor growth delay and the highest survival. We found that PARP inhibition increases radiosensitization independent of BRCA1 status for both protons and photons. The combination of protons and PARP inhibition was the most effective in decreasing clonogenic cell survival, increasing DNA damage, and delaying tumor growth.  \nKeywords DNA repair inhibitor, PARP inhibitor, Radiosensitization, Proton therapy, Radiobiology, Radiotherapy  \nPoly(ADP-ribose) polymerases (PARPs) are a family of proteins involved in several cellular processes. PARP1 is the most important member of the PARP family because of its involvement in DNA damage response (DDR) and DNA repair. The catalytic activity of PARP1 results in the recruitment of several proteins involved in DDR. PARP1 is actively involved in base excision repair, which repairs base damage and single-strand break (SSB) lesions1. PARP1 is also involved in sensing double-strand break (DSB) lesions1. In homologous recombination (HR), it helps to recruit BRCA12. However, PARP1 has also been implicated in reducing HR by PARylation of BRCA1, which stabilizes BRCA1’s interaction with receptor-associated protein 80 (RAP80), limiting its function3. It is likely that PARP1 helps to “fine-tune” the level of HR1,3. PARP1 also has roles in non-homologous end joining (NHEJ), where it promotes the kinase activity of the DNA-dependent protein kinase catalytic subunit4. PARP1 has also been linked to alternative-NHEJ repair1. PARP1 is best known for its clinical relevance in BRCA1-mutant cancers. The loss of functional BRCA1 leads to a synthetic lethal relationship with PARP1 inhibition. The mechanistic basis for this relationship is thought to lie in the accumulation of SSB lesions and base damage that ordinarily would be repaired by PARP1 activity. During replication, these lesions become DSB lesions that generally do not create suitable substrates for NHEJ machinery and therefore require HR and functional BRCA1 activity to maintain cell viability.  \n1Division of Radiation Oncology, Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2Department of Biosciences, Rice University, Houston, TX, USA. 3Division of Radiation Oncology, Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4Present address: Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5Present address: Department of Chemistry, Emory Unive","cbCaicDlqlduBDB3","https://ap.wps.com/l/cbCaicDlqlduBDB3","pdf",10222664,15,"English","# Study overview and rationale\n# Experimental design and in vitro findings\n## Effects on cell kill and DNA damage markers\n## Cell cycle and senescence outcomes\n# In vivo efficacy and survival results\n# Background on PARP1, BRCA1, and clinical relevance","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To determine whether PARP inhibition can radiosensitize breast cancer models to proton therapy and improve response relative to standard photon radiotherapy.\"},{\"question\":\"Does the radiosensitization depend on BRCA1 mutation status?\",\"answer\":\"No. PARP inhibition increased the radiosensitization effects for both photons and protons independent of BRCA1 status.\"},{\"question\":\"What combination produced the strongest anti-tumor effect in vivo?\",\"answer\":\"The combination of proton irradiation (3.99 keV/µm) with PARP inhibition resulted in the greatest tumor growth delay and the highest survival.\"}]","PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy | PDF",1790038404,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd136f602b03daa02cb92207f6b60ea2.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/041e5523e0542e80aef34f47613279ba.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac4740073ddf81a9f6860bb795494bea.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2bb27d62f391892f10489ba651aa0f73.webp",980,1287]